Stay updated on Nivolumab Safety in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Safety in Lung Cancer Clinical Trial page.

Latest updates to the Nivolumab Safety in Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3. This is a minor technical update that does not affect study content or user-facing features.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed prior notices, including the government-funding status notice and Revision: v3.4.1; these are administrative updates to the website's metadata rather than study information.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a government funding status notice and updated the site revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a glossary toggle, new navigation and document links (FDA Safety Alerts and Recalls, BMS Clinical Trial Information, Patient Recruiting), and attached PDFs; removed No FEAR Act data from the footer. No core study data or outcomes were changed.SummaryDifference53%

- Check62 days agoChange DetectedThe revision tag on the page was updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check84 days agoChange DetectedA new consolidated Locations section was added, listing multiple region-specific groups (e.g., Alabama, California, Montana, New York, Pennsylvania, Ontario, Aichi-ken, Osaka, Tokyo, Eastern Cape, Gauteng, Western Cape). The previous individual location groups and the older revision label were removed.SummaryDifference1%

Stay in the know with updates to Nivolumab Safety in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Safety in Lung Cancer Clinical Trial page.